Industry News

Join WhatsApp Channel 

GPAT caoching
  • Jagsonpal Pharmaceuticals to Acquire Group Pharma’s Wellness Portfolio in ₹46.7 Crore Deal
    30 September 2026

    Jagsonpal Pharmaceuticals to Acquire Group Pharma’s Wellness Portfolio in ₹46.7 Crore Deal

    Jagsonpal Pharmaceuticals Limited has entered into a Business Transfer Agreement (BTA) with Group Pharmaceuticals Limited to acquire its Wellness Portfolio, in a transaction that could have a total consideration of up to ₹46.7 crore.

    According to the company’s regulatory disclosure dated September 23, 2026, the acquisition will be undertaken on a going-concern basis through a slump sale. Jagsonpal said the move is aimed at strengthening its pharmaceutical portfolio, expanding its presence across relevant therapeutic segments and increasing its market reach.

  • Roche Reports Positive Phase III Results for Sefaxersen in IgA Nephropathy
    29 September 2026
    Roche Reports Positive Phase III Results for Sefaxersen in IgA Nephropathy
    Roche has announced positive interim results from its ongoing Phase III IMAgINATION study evaluating sefaxersen, an investigational treatment for adults living with primary IgA nephropathy (IgAN).
  • AbbVie’s JUVMO Gets FDA Approval for Parkinson’s Disease: New D1/D5 Targeted Treatment Approved in the U.S.
    29 September 2026
    AbbVie’s JUVMO Gets FDA Approval for Parkinson’s Disease: New D1/D5 Targeted Treatment Approved in the U.S.

    AbbVie’s JUVMO (tavapadon) has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of Parkinson’s disease in adults. The once-daily oral medicine introduces a different approach to dopamine-based treatment by selectively targeting D1/D5 receptors.

    AbbVie announced on September 28, 2026, that the FDA approved JUVMO tablets for adults with Parkinson’s disease. The company describes JUVMO as the first and only selective D1/D5 receptor agonist approved for adults with Parkinson’s disease.

  • Eli Lilly Sets 2040 Goal to Expand Diabetes and Obesity Treatment Access in Developing Markets
    29 September 2026
    Eli Lilly Sets 2040 Goal to Expand Diabetes and Obesity Treatment Access in Developing Markets

    Eli Lilly and Company has announced the launch of the Lilly Change the Course Commitment, a new global health initiative aimed at addressing gaps in access to diabetes and obesity treatments in low- and middle-income countries (LMICs). The company has set a goal of achieving parity in the number of patients treated with its diabetes and obesity medicines in resource-limited settings and high-income countries before 2040.

  • BioNTech to Close Three German Sites After Buyer Search Fails, Affecting Up to 1,860 Jobs
    29 September 2026
    BioNTech to Close Three German Sites After Buyer Search Fails, Affecting Up to 1,860 Jobs
    German biotechnology company BioNTech is set to close three of its sites in Germany after efforts to find potential buyers for the facilities did not result in agreements. The planned closures are part of the companys broader strategy to consolidate its global manufacturing network and redirect resources toward its growing oncology pipeline.
  • Takeda and Dr. Reddy’s Partner to Promote and Distribute QDENGA® in India’s Private Pediatric and Adult Market
    18 September 2026
    Takeda and Dr. Reddy’s Partner to Promote and Distribute QDENGA® in India’s Private Pediatric and Adult Market
    QDENGA®, across India’s private market for pediatric and adult vaccination in India. Subject to completion of applicable processes with local authorities, the vaccine is anticipated to become available in the first half of 2027.
  • FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
    18 September 2026
    FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
    Sanfilippo syndrome type A is a rare inherited disorder that primarily affects the brain and nervous system. Children with the condition can experience progressive loss of cognitive, language and other developmental abilities. Before this approval, there was no FDA-approved treatment specifically designed to address the underlying cause of MPS IIIA
  • Dr. Reddy’s Expands Lenacapavir Partnership With Gilead for Future HIV Prevention Access
    17 September 2026
    Dr. Reddy’s Expands Lenacapavir Partnership With Gilead for Future HIV Prevention Access

    Dr. Reddy’s Laboratories has expanded its collaboration with Gilead Sciences through a royalty-free, non-exclusive voluntary licensing agreement covering investigational once-yearly lenacapavir for HIV prevention. The agreement builds on the companies’ existing 2024 licensing arrangement for lenacapavir and is intended to support future manufacturing readiness, technology transfer and supply planning in licensed territories.

  • Sanofi to Transfer 20 Mature Medicines and 3 Manufacturing Sites to Cheplapharm in Strategic Partnership
    16 September 2026
    Sanofi to Transfer 20 Mature Medicines and 3 Manufacturing Sites to Cheplapharm in Strategic Partnership

    Sanofi and Cheplapharm have announced plans to establish a new strategic partnership focused on the management of mature medicines. Under the proposed agreement, Cheplapharm will take over 20 mature medicines and three Sanofi manufacturing sites worldwide, while Sanofi will receive a 26.4% equity stake in Cheplapharm.

  • GSK’s Shingrix Prefilled Syringe Approved in Japan for Shingles Prevention
    11 September 2026
    GSK’s Shingrix Prefilled Syringe Approved in Japan for Shingles Prevention

    GSK plc has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a prefilled syringe presentation of Shingrix (Recombinant Zoster Vaccine, RZV) for the prevention of shingles (herpes zoster). The announcement was made on September 10, 2026.

Subscribe to Industry News